In contrast, the basis for APOBEC3B mutation of the HBX protein of HBV is to promote the development of liver cancer in liver cancer cells (i.e., after liver cancer has occurred) (69), which does not contradict our hypothesis that APONEC3B inhibits the occurrence of liver cancer at the stage of HBV infection by degrading ccc DNA and DNA. Here, APOBEC3B is linked to liver cancer.